Monoclonal Mouse anti‑Human NCOA3 / SRC‑3 / AIB1 Antibody (clone 2C11B12, Amino Acid: 1‑200, WB) LS‑C758556
Monoclonal Mouse anti‑Human NCOA3 / SRC‑3 / AIB1 Antibody (clone 2C11B12, Amino Acid: 1‑200, WB) LS‑C758556
Antibody:
NCOA3 / SRC-3 / AIB1 Mouse anti-Human Monoclonal (Amino Acid: 1-200) (2C11B12) Antibody
Format:
Unconjugated, Unmodified
Overview
Antibody:
NCOA3 / SRC-3 / AIB1 Mouse anti-Human Monoclonal (Amino Acid: 1-200) (2C11B12) Antibody
Format:
Unconjugated, Unmodified
Specifications
Description
AIB1 antibody LS-C758556 is an unconjugated mouse monoclonal antibody to human AIB1 (NCOA3 / SRC-3) (Amino Acid: 1-200). Validated for WB.
Target
Human NCOA3 / SRC-3 / AIB1
Synonyms
NCOA3 | ACTR | AIB1 | BHLHe42 | CAGH16 | CBP-interacting protein | CTG26 | AIB-1 | P/CIP | TNRC14 | TRAM-1 | Nuclear receptor coactivator 3 | PCIP | RAC-3 | SRC3 | TNRC16 | KAT13B | NCoA-3 | SRC-3
Reactivity
Human
(tested or 100% immunogen sequence identity)
Clonality
IgG1
Monoclonal
Conjugations
Unconjugated
Immunogen
Purified recombinant fragment of NCOA3 (aa1-200) expressed in E. Coli. ;
Epitope
Amino Acid: 1-200
Applications
- Western blot (1:500 - 1:2000)
Usage
Applications should be user optimized.
Presentation
Ascites, 0.03% sodium azide
Storage
Short term: 4°C; Long term: -20°C. Avoid freeze-thaw cycles.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
About NCOA3 / SRC-3 / AIB1
Featured Products
Species:
Human
Applications:
Western blot
Source:
E. coli
Tag:
His-T7
Species:
Human, Mouse
Applications:
IHC, IHC - Paraffin, Immunofluorescence, Western blot
Reactivity:
Bovine
Range:
1.56-100 ng/ml
Species:
Human
Applications:
IHC, IHC - Frozen, ICC, Western blot, Immunoprecipitation, Functional Assay
Reactivity:
Human
Range:
0.156-10 ng/ml
Request SDS/MSDS
To request an SDS/MSDS form for this product, please contact our Technical Support department at:
Technical.Support@LSBio.com
Requested From: United States
Date Requested: 5/5/2024